connbio | Abstract Finder

Abstract Number: 285 – Lovesick: Examining Couples Health during Myeloma Transplant

Presenter: Ashley Rosko, MDSession: 907. Outcomes Research: Plasma Cell Disorders: Quality Matters and Key Outcomes in Multiple MyelomaDate & Time: Saturday, December 7, 2024 2:30 PM–2:45 PMLocation: Marriott Grand Ballroom 5-6 (Marriott Marquis San Diego...

Abstract Number: 284 – Balancing Treatment Intervals and Quality of Life in Multiple Myeloma Patients: Patient Perspectives and Recommendations

Presenter: Anna FleischerSession: 907. Outcomes Research: Plasma Cell Disorders: Quality Matters and Key Outcomes in Multiple MyelomaDate & Time: Saturday, December 7, 2024 2:15 PM–2:30 PMLocation: Marriott Grand Ballroom 5-6 (Marriott Marquis San Diego...

Abstract Number: 283 – National Healthtree Survey on Pain and Opioid Use Patterns and Perceptions Among Patients with Multiple Myeloma

Presenter: Karen Sweiss, PharmDSession: 907. Outcomes Research: Plasma Cell Disorders: Quality Matters and Key Outcomes in Multiple MyelomaDate & Time: Saturday, December 7, 2024 2:00 PM–2:15 PMLocation: Marriott Grand Ballroom 5-6 (Marriott Marquis San Diego...

Abstract Number 1045: Feasibility, Safety and Efficacy of Oral Maintenance Therapy with Venetoclax Plus Decitabine/Cedazuridine after Venetoclax Plus FluBu2 for High Risk MDS/AML Undergoing RIC Allo-HCT

Background: We previously demonstrated that adding venetoclax to reduced intensity conditioning (RIC) chemotherapy for patients undergoing alloHCT followed by maintenance therapy with intravenous azacitidine and venetoclax (Ven) was safe and associated with...

Abstract Number 1007: Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML

Background Leukemic stem cells have high expression of CD123 compared to normal hematopoietic stem cells. CD123 is therefore an attractive therapeutic target in myeloid neoplasms including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic...

Abstract Number: 285 – Lovesick: Examining Couples Health during Myeloma Transplant

Abstract Number: 284 – Balancing Treatment Intervals and Quality of Life in Multiple Myeloma Patients: Patient Perspectives and Recommendations

Abstract Number: 283 – National Healthtree Survey on Pain and Opioid Use Patterns and Perceptions Among Patients with Multiple Myeloma

Abstract Number 1045: Feasibility, Safety and Efficacy of Oral Maintenance Therapy with Venetoclax Plus Decitabine/Cedazuridine after Venetoclax Plus FluBu2 for High Risk MDS/AML Undergoing RIC Allo-HCT

Abstract Number 1007: Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML

Recent Posts

Recent Comments

Archives

Categories

Meta